CymaBay Therapeutics Statistics Share Statistics CymaBay Therapeutics has 114.78M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 114.78M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 96.64M Failed to Deliver (FTD) Shares 171 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 4.45M, so 0% of the outstanding
shares have been sold short.
Short Interest 4.45M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1.57
Valuation Ratios The PE ratio is -23.81 and the forward
PE ratio is -541.33.
CymaBay Therapeutics's PEG ratio is
0.89.
PE Ratio -23.81 Forward PE -541.33 PS Ratio 80.73 Forward PS 13.8 PB Ratio 8.58 P/FCF Ratio -34.37 PEG Ratio 0.89
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for CymaBay Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.96,
with a Debt / Equity ratio of 0.39.
Current Ratio 10.96 Quick Ratio 10.96 Debt / Equity 0.39 Debt / EBITDA -1.34 Debt / FCF -1.57 Interest Coverage -5.37
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $307.65K Profits Per Employee $-1.04M Employee Count 101 Asset Turnover 0.07 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 0.32, so CymaBay Therapeutics's
price volatility has been higher than the market average.
Beta 0.32 52-Week Price Change n/a 50-Day Moving Average 28.94 200-Day Moving Average 18.65 Relative Strength Index (RSI) 80.99 Average Volume (20 Days) 3,944,615
Income Statement In the last 12 months, CymaBay Therapeutics had revenue of 31.07M
and earned -105.37M
in profits. Earnings per share was -0.99.
Revenue 31.07M Gross Profit 30.39M Operating Income -101.68M Net Income -105.37M EBITDA -85.74M EBIT -86.42M Earnings Per Share (EPS) -0.99
Full Income Statement Balance Sheet The company has 206.53M in cash and 114.49M in
debt, giving a net cash position of 92.04M.
Cash & Cash Equivalents 206.53M Total Debt 114.49M Net Cash 92.04M Retained Earnings -978.23M Total Assets 434.69M Working Capital 366.96M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -72.53M
and capital expenditures -445K, giving a free cash flow of -72.98M.
Operating Cash Flow -72.53M Capital Expenditures -445K Free Cash Flow -72.98M FCF Per Share -0.69
Full Cash Flow Statement Margins Gross margin is 97.81%, with operating and profit margins of -327.23% and -339.1%.
Gross Margin 97.81% Operating Margin -327.23% Pretax Margin -339.1% Profit Margin -339.1% EBITDA Margin -275.94% EBIT Margin -327.23% FCF Margin -234.85%
